SCHEMBL56282

SCHEMBL56282

CC(C)(OC(=O)Cl)C(Cl)(Cl)Cl

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13485473 0.80
SCHEMBL291087 0.80 THRB (0.35) THRB
SCHEMBL291088 0.78 ALDH1A1 (0.33) THRB
SCHEMBL13434035 0.78 GAA (0.42) THRB
SCHEMBL5015809 0.78 THRB (0.33) THRB
SCHEMBL8119240 0.77
SCHEMBL14962814 0.77
SCHEMBL16823234 0.76 THRB (0.32) THRB
SCHEMBL20109904 0.76 ELANE (0.32) THRB
SCHEMBL80733 0.76 LMNA (0.35) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635941-A1 PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE Nouryon Chemicals International B.V. (NL) 2025-10-22 EP claimed
EP-4471010-B1 PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE NOURYON CHEMICALS INT BV (NL) 2025-06-04 EP claimed
US-20240400490-A1 PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE NOURYON CHEMICALS INTERNATIONAL B.V. (NL) 2024-12-05 US claimed
EP-4471010-A1 PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE Nouryon Chemicals International B.V. (NL) 2024-12-04 EP claimed
CN-118696027-A Synthetic intermediates for preparing ROCK inhibitors and improved methods 爱尔康公司 2024-09-24 CN claimed
CN-108601355-B Process for preparing kinase inhibitors and intermediates thereof 爱瑞制药公司 2021-03-30 CN claimed
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN claimed
WO-2006012425-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2006-02-02 WO claimed
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 US claimed
US-20040267007-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor CORIXA CORPORATION 2004-12-30 US claimed
EP-0889885-B1 METHOD FOR SELECTIVE PROTECTION OF BACCATIN DERIVATIVES AND ITS APPLICATION TO TAXANE SYNTHESIS SERIPHARM (FR) 2002-05-29 EP claimed
EP-4635941-A1 PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE Nouryon Chemicals International B.V. (NL) 2025-10-22 EP disclosed
US-12410208-B2 (2-acetamidyl)thio-beta-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-09-09 US disclosed
US-12404295-B2 (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-09-02 US disclosed
US-12365927-B2 Engineered ketoreductase polypeptides CODEXIS, INC. (US) 2025-07-22 US disclosed
EP-0176308-A2 2-(Pyridylalkylenesulfinyl) benzimidazoles THE UPJOHN COMPANY (US) 1986-04-02 EP disclosed
EP-0174054-A2 Heat-sensitive element for use in a thermal imaging method POLAROID CORPORATION (US) 1986-03-12 EP disclosed
US-4294959-A Selectively protected 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and their production BAYER AKTIENGESELLSCHAFT (DE) 1981-10-13 US disclosed
EP-0009201-A1 Selectively protected 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, method for their preparation and their use as intermediates BAYER AG (DE) 1980-04-02 EP disclosed
US-4111933-A PROTECTION OF FUNCTIONAL GROUPS DURING REACTION AND THEIR SUBSEQUENT RESTORATION BAYER AKTIENGESELLSCHAFT (DE) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400490-A1 PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE GPX4, PRDX4, PRDX2 THRB 3147/4885
US-20040267007-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor DDOST, STT3A, STT3B THRB 4075/4885
US-12410208-B2 (2-acetamidyl)thio-beta-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 THRB 170/4885
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor DDOST, AGL, GALE THRB 3959/4885
US-12404295-B2 (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 THRB 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.